OnKure Therapeutics (NASDAQ:OKUR) Stock Rating Lowered by JonesTrading

Key Points

• JonesTrading downgraded OnKure Therapeutics (NASDAQ:OKUR) from a strong-buy to a hold, and the MarketBeat consensus rating is Hold with a $27 consensus price target.
• OnKure reported Q1 EPS of ($1.11), missing the consensus ($0.74) by $0.37, and analysts project a full-year EPS of -2.74.
• Shares trade around $3.96 (1‑year range $1.70–$5.38) with a market cap of about $54.1 million, and institutional investors own roughly 90.98% of the stock.

OnKure Therapeutics (NASDAQ:OKUR - Get Free Report) was downgraded by equities research analysts at JonesTrading from a "strong-buy" rating to a "hold" rating in a note issued to investors on Thursday,Zacks.com reports.

OKUR has been the subject of several other research reports. Weiss Ratings upgraded shares of OnKure Therapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Friday, April 24th. HC Wainwright decreased their price objective on shares of OnKure Therapeutics from $34.00 to $27.00 and set a "buy" rating for the company in a research note on Monday, March 16th. Finally, Wall Street Zen upgraded shares of OnKure Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, March 14th. One investment analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, OnKure Therapeutics currently has a consensus rating of "Hold" and a consensus price target of $27.00.

OnKure Therapeutics Price Performance

Shares of OKUR opened at $3.96 on Thursday. OnKure Therapeutics has a 1-year low of $1.70 and a 1-year high of $5.38. The stock has a market cap of $54.13 million, a PE ratio of -0.91 and a beta of 0.36. The firm has a fifty day moving average price of $4.10 and a 200 day moving average price of $3.32.

OnKure Therapeutics (NASDAQ:OKUR - Get Free Report) last released its quarterly earnings data on Tuesday, May 5th. The company reported ($1.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.74) by ($0.37). As a group, equities analysts expect that OnKure Therapeutics will post -2.74 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. XTX Topco Ltd acquired a new position in OnKure Therapeutics in the second quarter valued at $25,000. Jane Street Group LLC acquired a new position in shares of OnKure Therapeutics during the fourth quarter worth about $56,000. Hsbc Holdings PLC acquired a new position in shares of OnKure Therapeutics during the fourth quarter worth about $58,000. Barclays PLC increased its stake in shares of OnKure Therapeutics by 4,286.8% during the fourth quarter. Barclays PLC now owns 27,242 shares of the company's stock worth $79,000 after acquiring an additional 26,621 shares during the period. Finally, Rangeley Capital LLC purchased a new stake in OnKure Therapeutics during the second quarter worth about $71,000. 90.98% of the stock is currently owned by institutional investors and hedge funds.

About OnKure Therapeutics

OnKure Therapeutics, Inc NASDAQ: OKUR is a clinical-stage biopharmaceutical company focused on the development of novel therapies for oncology and autoimmune diseases. Headquartered in Westlake Village, California, OnKure is advancing small molecule drug candidates designed to modulate key signaling pathways implicated in cancer cell growth and immune system function.

The company's lead oncology asset, OKI-179, is an orally available histone deacetylase (HDAC) inhibitor being evaluated in Phase I and Phase II clinical studies for a range of solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.